Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.54 |
| ▸ | ACE | P12821 | 6/20 | 0.54 |
| ▸ | MME | P08473 | 4/20 | 0.54 |
| ▸ | CPA1 | P15085 | 4/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846520 | 0.96 | ACE (0.58) | BACE1ACEMMECPA1ACE2 | |
| SCHEMBL29850820 | 0.95 | ACE (0.57) | BACE1ACEMMECPA1ACE2 | |
| SCHEMBL31514336 | 0.92 | BACE1 (0.51) | BACE1ACEMMECPA1ACE2 | |
| SCHEMBL30713700 | 0.91 | ACE (0.61) | BACE1ACEMMECPA1ACE2 | |
| SCHEMBL30051286 | 0.90 | ACE (0.65) | ACEMMECPA1ACE2 | |
| SCHEMBL30799476 | 0.88 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL30799933 | 0.88 | BACE1 (0.54) | BACE1CTSD | |
| SCHEMBL30051194 | 0.88 | MME (0.58) | ACEMMECPA1ACE2 | |
| SCHEMBL30051600 | 0.88 | ACE (0.68) | ACEMMECPA1ACE2 | |
| SCHEMBL30799521 | 0.87 | BACE1 (0.58) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885ACE 736/4885MME 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.